J&J’s Commitment To Diversification Through OTCs Rewarded In Q2

This article was originally published in The Tan Sheet

21 Jul 2008
News

Eileen Francis eileen.francis@informa.com

Executive Summary

Johnson & Johnson's second-quarter results show the firm's commitment to broader diversification with the 2006 purchase of Pfizer's consumer business was shrewd. The firm's over-the-counter business countered weak performance in the pharma sector

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS101891

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS101891

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

J&J’s Commitment To Diversification Through OTCs Rewarded In Q2

News

Executive Summary

Related Content

FDA approves Zyrtec OTC

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert